Large-scale production of APIs to be established in Russia

Russian Investment fund Elbrus Capital is considering establishing a large-scale production of pharmaceutical substances in Russia that will take place on the basis Active Component, one if Russia’s leading producer of active pharmaceutical ingredients (APIs), reports The Pharma Letter’s local correspondent.

As part of these plans, Elbrus Capital recently completed the acquisition of minority stake in Active Component, planning a further expansion of its production. This will be in the form of the building a new plant, that will focus on the production of active pharmaceutical substances. The value of investments in the project is 2 billion roubles ($40 million). The launch of the first phase is scheduled for the first half of 2019. The factory will reach its design capacity by 2020.

Currently, Active Component produces more than 50 various pharmaceutical substances. Its volume of production is estimated at 60 tons per year. The company holds 12.2% of the Russian market of substances.